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Abstract: Viral gastroenteritis is an important cause of morbidity and mortality worldwide, being
particularly severe for children under the age of five. The most common viral agents of gastroenteritis
are noroviruses, rotaviruses, sapoviruses, astroviruses and adenoviruses, however, no specific
antiviral treatment exists today against any of these pathogens. We here discuss the feasibility of
developing a broad-spectrum antiviral treatment against these diarrhea-causing viruses. This review
focuses on the viral polymerase as an antiviral target, as this is the most conserved viral protein
among the diverse viral families to which these viruses belong to. We describe the functional and
structural similarities of the different viral polymerases, the antiviral effect of reported polymerase
inhibitors and highlight common features that might be exploited in an attempt of designing such
pan-polymerase inhibitor.
Keywords: RNA viruses; DNA viruses; viral polymerase; antiviral; norovirus; rotavirus
1. Introduction: The Need and the Concept of Antiviral Treatment for Viral Diarrhea
Acute gastroenteritis (AGE) occurs worldwide and is an important health issue that affects all age
groups. Human rotaviruses (HRV), dsRNA viruses belonging to the Reoviridae family, are the most
important cause of viral AGE in children <5 years, annually resulting in 215,000 deaths [1]. After the
introduction of two rotavirus vaccines, human noroviruses (HNoV), (+)ssRNA viruses belonging
to the Caliciviridae family, have been gaining impact in this age group, becoming in fact the most
common viral agent of AGE in all age groups, resulting in 200,000 deaths per year [2]. Other human
diarrhea-causing viruses such as astroviruses (HAstV, Astroviridae, (+)ssRNA), sapoviruses (HSaV,
Caliciviridae, (+)ssRNA) and adenoviruses type 40 and 41 (HAdV, Adenoviridae, dsDNA) are common
agents of AGE in young children, causing more moderate disease and being less prevalent than
rota- and noroviruses. Infection with these viruses occurs via the fecal-oral route, by ingestion of
contaminated food or water and by person-to-person contact. Large outbreaks occur frequently,
disturbing the functioning of health institutions, long-term care facilities and other semi-closed
environments [3].
AGE manifests suddenly, with vomiting and watery non-bloody diarrhea being the most common
symptoms. Differentiating the causative agent based on symptoms alone is unfeasible, thus specific
diagnostic tests are required. Although AGE is normally self-limiting, it can be debilitating, with
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prolonged and severe disease occurring in vulnerable populations, namely young children, the elderly
and immunocompromised individuals. There are currently no specific antiviral drugs available
and treatment is limited to supportive therapy with oral rehydration salts (ORS). Outbreak control
and prevention strategies are limited to the use of disinfectants and hand sanitizers (which are not
highly efficient) or by limiting human exposure through closing down facilities (e.g., hospital wards).
A specific and efficacious intervention strategy to treat diarrheal disease and to contain it, preventing
virus spreading, is highly desirable.
Highly potent and effective antivirals have been developed in the last decades against herpes
viruses, HIV, HCV and HBV [4]. Specific treatment for acute viral infections such as respiratory
infections with RSV are now on the horizon. Achieving effective antiviral treatment for acute diarrhea
should thus not be doomed impossible, but needs to be conceptually well-designed, highly efficient
and made available timely to the patient. Challenges certainly include the variety of agents but
also the installed culture of undervaluing the discomfort and morbidity inflicted by an episode of
gastroenteritis. Moreover, patients with primary immune deficiencies, transplant recipients and other
immunocompromised individuals can face months of diarrheal episodes thus making this a pressing
matter [5–7].
It is unrealistic to consider that one antiviral could be developed against each virus that causes
AGE, therefore the development of a broad-spectrum antiviral effective against multiple viruses would
be preferable and the clinical use would then be made simpler. Rapid laboratory diagnostics should
be paired with the start of treatment to ensure the cause is viral and thus the agent susceptible to
the treatment. Some broad-spectrum antivirals such as ribavirin are available, but the existence of
a syndrome-based single drug (or, eventually, a combination of drugs) would be innovative and
highly beneficial to the patient that could finally have access to fast-acting specific treatment for
diarrheal disease. Initiating treatment early, i.e., less than two days from the onset of symptoms as is
recommended for influenza virus infections [8], would greatly increase the chances of success. On the
other hand, for those chronically infected this might be much less critical; a reduction of shedding and
symptoms could already be considered a positive outcome. Antiviral prophylaxis would be desirable
for those in high risk for severe and prolonged disease, as mentioned above.
An antiviral drug could be designed with multiple targets in sight, namely the viral surface
proteins thus preventing the start of infection or virion release, the viral genome replication machinery
hence targeting enzymes such as the polymerase, or cellular factors thus inhibiting virus-host
interactions. In this review, we explore the viral polymerase as a target for a syndrome-based approach
to antiviral therapy. Structural and functional information on the polymerases of calici-, rota-, adeno-
and astroviruses is compared, highlighting common features which can serve as a starting point for
the in silico design of novel small-molecule inhibitors with pan-antiviral activity. Potential challenges
and limitations to this approach are also discussed.
2. The Viral Polymerase as an Antiviral Target
As major diarrhea-causing viruses belong to different viral families, their viral polymerases show
substantial differences in functionalities and interactions with other factors to exert their function.
Nonetheless, the viral polymerase represents the most conserved target among diverse viral families,
as it maintains the same overall structure and functional motifs, despite significant amino-acid sequence
variations [9,10]. The viral polymerase is an excellent antiviral target, as proven by the successful
antivirals developed against herpesviruses (e.g., acyclovir), HCV (e.g., sofosbuvir), HIV (various
nucleoside and non-nucleoside reverse transcriptase inhibitors). Also for RSV (Lumicitabine or
ALS-8176) and Ebola virus (Remdesivir or GS-5734) potent nucleoside polymerase inhibitors are in
development [11]. This protein therefore represents the most suitable choice to identify broad-spectrum
antiviral agents that can block the replication of all, or most, diarrhea-inducing viruses at the same time.
Viruses 2019, 11, 173 3 of 18
2.1. Functional and Structural Comparison of the Viral Polymerase in Diarrhea-Causing Viruses
The viral RNA-dependent RNA-polymerase (RdRp) of noro- and sapoviruses [12], which belong to
two genera within theCaliciviridae, replicates their (+)ssRNA genome by initiating RNA synthesis according
to two different modes, de novo and primed by VPg (viral protein genome-linked) [13]. Sapovirus and
norovirus RdRps share high structural analogies, with a sequence similarity of 34% [14]. A crystal structure
is available for HSaV in the apo form [14], while several crystal structures are available for human and
murine norovirus (MNV) RdRp, including the apo form and multiple complexes with ion cofactors, RNA
elements, nucleotide analogues and non-nucleoside inhibitors [9,15–20]. The structures of HNoV and
HSaV RdRps and their superimposition are illustrated in Figure 1a-c.
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Figure 1. (a) Three-dimensional structure and domains of ( r alk virus, GI.1) in
complex with RNA template strand, RNA growing stra d and 5-nitrocytidine (PDB ID 3BSN, resolution
1.8 Å); (b) HSaV RdRp (Sapporo virus, Hu/SV/Man/1993/UK) in its apo form (PDB ID 2CKW,
resolution 2.3 Å); (c) structural superimposition of the two RdRps.
HNoV and HSaV RdRps share a three dimensio al organization that resembles a right hand with
palm, thumb and fingers domains, and show the presence of six broadly known polymerase-conserved
sequence and structural motifs A-F [21,22], along with the motif G and motif H [23]. The RNA template,
primer and incoming NTP bind to the large central active site. The two ion cofactors are coordinated
in the catalytic site by aspartic acids of the palm subdomain, where the conserved catalytic GDD
sequence (motif C) is located. Three allosteric sites have been identified for the HNoV RdRp, according
to the binding of co-crystallized non-nucleoside inhibitors [24].
HRVs are characterized by a segmented dsRNA and their RNA synthesis takes place within subviral
particles called viroplasms. Viral genome replication is carried out, following a particle-associated
mechanism, by the viral dsRdRp VP1, which interacts in a replication complex with different nucleic
acid and protein elements [25–27]. Despite significant functional differences with ssRNA polymerases,
VP1 presents the conserved motifs A–H and a right-hand shape, as confirmed by different crystal structures
available for the apoenzyme and complexes with RNA and GTP (Figure 2) [27].
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Figure 2. (a) Domains of the 1 co-crystallised with an RNA fragment and GT (PDB ID 2R7X,
resolution 2.8 Å); (b) colour-coded otifs -F in the 2R7X crystal structure, with the catalytic residues
Asp631 and Asp632 highlighted (part of the conserved GDD sequence).
Similarly to Caliciviridae, HAstVs are characterized by a (+) ssRNA genome, but they represent one of
the least studied enteric viruses, and much has to be determined for their viral proteins. Their RdRp is
encoded in the open reading frame (ORF) 1b, and it belongs to the supergroup 1 of RNA-polymerases [28],
relying on the VPg to initiate transcription [29,30]. Crystal structures are available only for HAstV capsid
elements [31–34]. In order to compare the structure of HAstV RdRp to the other viral polymerases, we have
used the RdRp domain from the HAstV-1 non-structural polyprotein sequence Q67726 [35] to run a
DELTA-BLAST search [36] within the Protein Data Bank [37], to find the most homologous proteins with
an associated crystal structure. Among the closest viral RdRps found were the ones of Sapporo virus (HSaV
GI) (16% sequence identity) and Norwalk virus (HNoV GI) (18% sequence identity), which we chose as the
template (PDB ID 3BSO [15]) to prepare a homology model for astrovirus RdRp using MOE2018.10 [38].
The sequence alignment, manually adjusted from the one obtained on Clustal Omega [39], and the structure
of the final model are shown in Figure 3.
The Ramachandran plot (data not sho n) confirmed that all residues of the catalytic site in our
model are in the allowed region f r t eir ac e dihedral angles, indicating its reliability to assess
in silico potential nucleoside in i i ti g the active site. Such models cannot be used with
confidence to evaluate allosteric sites.
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Differently from the other diarrhea-causing viruses, HAdVs have a linear dsDNA genome,
replicated by the viral DNA polymerase (HAdV Pol) according to a protein-primed mechanism [40].
HAdV Pol belongs to the B-family of DNA polymerases, and it contains an exonuclease domain
responsible for its proofreading function. Differently from RNA polymerases, HAdV Pol also presents
two extra subdomains, TPR1 and TPR2, whose function is not completely understood. HAdV Pol
forms a replication complex with viral and cellular factors to produce viral genome duplexes [41],
with a mechanism similar to the DNA replication of bacteriophages, including the Bacillus subtilis
bacteriophage f29 [42]. While a crystal structure is not available for HAdV Pol, structural data is
available for the bacteriophage f29 DNA polymerase [43], and we used its ternary complex with a
DNA primer and substrate (PDB 2PYL) to prepare a homology model for HAdV Pol from the sequence
of HAdV serotype 40 (UniProtKB entry P48311), using MOE2018.10 [38]. The two prot in sequences
were manually aligned to match reported functional alignments (Figure 4a) [44], an the final model
for HAdV Pol is shown in Figure 4b. As with our HAstV RdRp m del, also this one can be used to
evaluate the binding of nucleoside inhibitors, but not to evaluate allosteric ones.
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Fig 4. (a) Sequence alignment betwe n the bacteriophage f29 DNA polymerase and the polymerase
domain of HAdV F serotype 40; (b) final model for the AdV Pol, including the nucleic acid and NTP
components minimized from the template.
While it remains challenging to identify a broad-spectrum agent that targets all five polymerases,
some overall structural similarities might be exploited to attempt to design such a pan-polymerase
inhibitor. Although identifying an allosteric site common to all polymerases appears unfeasible,
the enzyme active site, in particular the incoming nucleotide subsite, is relatively conserved across
the different viruses (Figure 5). This represents a promising starting point to design broad-spectrum
nucleoside inhibitors.
Viruses 2019, 11, 173 7 of 18
  
Viruses 2019, 11, x; doi: www.mdpi.com/journal/viruses 
 
Figure 5. Similarities between RNA and DNA polymerases of diarrhea-causing viruses. (a) Incoming 
nucleotide binding pocket of the ternary complex of HNoV RdRp co-crystallised with 5-nitro cytidine 
triphosphate (PDB ID 3BSN); (b) incoming nucleotide binding pocket of the polymerase homology 
model obtained for HAdV. 
2.2. Known Polymerase Inhibitors of Diarrhea-Causing Viruses 
Different polymerase inhibitors have been found to be active against human noro-, sapo-, rota- 
and adenoviruses. Until now, no replication inhibitors have been reported for HAstV. The only 
explored antiviral agent, ribavirin, shows no clear efficacy in case reports [45,46]. 
2.2.1. Nucleoside Inhibitors 
Nucleoside analogues are generally phosphorylated by cellular enzymes to their triphosphate 
active form, which is incorporated by the viral polymerase in the growing nucleic acid strand, leading 
to chain termination or viral mutagenesis [47,48]. The nucleoside CMX521 (Figure 6) is the first drug 
candidate to be moved to phase I trials for the treatment of norovirus infections. It is active against 
multiple norovirus genotypes and effective in MNV-infected mice treated orally [49]. Ribavirin (RBV) 
has shown some inhibitory effect against NoV in vitro [50], but failed to demonstrate a clear benefit 
to patients [7]. Favipiravir (T-705), marketed in Japan to treat influenza [51], and its analogue T-1105 
inhibit MNV replication in cells [52,53], and showed variable efficacy in mouse models [54,55]. Other 
nucleoside analogues active against MNV and HNoV replication are 2’-C-methyl-cytidine (2CMC) 
[56,57], and its fluorinated analogue 2’-fluoro-2’-C-methyl-cytidine (2’-F-2CMC), the parent 
nucleoside of mericitabine [58]. Moreover, 2CMC and the 7-deaza-2’-C-methylated analogue of 
adenosine (7DMA) also inhibit the replication of sapovirus and rotavirus [59], hinting that the 
proposed broad-spectrum inhibition of multiple viral polymerases is feasible. Finally, 5-nitro cytidine 
triphosphate (NCT), whose parent nucleoside inhibits poliovirus and coxsackievirus B3 [60], and 2’-
amino cytidine triphosphate (ACT) have been co-crystallized with the HNoV RdRp [15,16]. 
i re 5. Si ilarities et ee a ol erases of iarr ea-ca si ir ses. (a) I co i
cle ti e i i c et f t e ter ar c le f c -cr stallise it 5- itr c ti i e
tri s t ( I ); ( ) i c i cl ti i i c t f t l r s l
l t i f .
2.2. Known Polymerase Inhibitors of Diarrhea-Causing Viruses
Different polymerase inhibitors have been found to be active against human noro-, sapo-, rota- and
adenoviruses. Until now, no replication inhibitors have been reported for HAstV. The only explored
antiviral agent, ribavirin, shows no clear efficacy in case reports [45,46].
2.2.1. Nucleoside Inhibitors
Nucleoside analogues are generally phosphorylated by cellular enzymes to their triphosphate
active form, which is incorporated by the viral polymerase in the growing nucleic acid strand, leading
to chain termination or viral mutagenesis [47,48]. The nucleoside CMX521 (Figure 6) is the first drug
candidate to be moved to phase I trials for the treatment of norovirus infections. It is active against
multiple norovirus genotypes and effective in MNV-infected mice treated orally [49]. Ribavirin (RBV)
has shown some inhibitory effect against NoV in vitro [50], but failed to demonstrate a clear benefit
to patients [7]. Favipiravir (T-705), marketed in Japan to treat influenza [51], and its analogue
T-1105 inhibit MNV replication in cells [52,53], and showed variable efficacy in mouse models [54,55].
Other nucleoside analogues active against MNV and HNoV replication are 2’-C-methyl-cytidine
(2CMC) [56,57], and its fluorinated analogue 2’-fluoro-2’-C-methyl-cytidine (2’-F-2CMC), the parent
nucleoside of mericitabine [58]. Moreover, 2CMC and the 7-deaza-2’-C-methylated analogue of
adenosine (7DMA) also inhibit the replication of sapovirus and rotavirus [59], hinting that the
proposed broad-spectrum inhibition of multiple viral polymerases is feasible. Finally, 5-nitro
cytidine triphosphate (NCT), whose parent nucleoside inhibits poliovirus and coxsackievirus B3 [60],
and 2’-amino cytidine triphosphate (ACT) have been co-crystallized with the HNoV RdRp [15,16].
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Few nucleoside analogues have been investigated also for their anti-rotavirus activity. 7DMA
and 2CMC inhibit in vitro HRV replication with a direct effect on the RdRp, as happens with
HNoV [59]. Ribavirin, 3-deazaguanine, 3-deazauridine and 9-(S)-(2,3-dihydroxy-propyl)adenine
show an effect which does not appear to be related with the viral RdRp [61], while the old antiviral
foscarnet (PFA), a pyrophosphate-mimic [62], adenosine-9-β-D-arabinofuranoside 5’-triphosphate
(Ara-ATP), a replication inhibitor for both RNA and DNA viruses, cytosine-9-β-D-arabinofuranoside
5’-triphosphate (Ara-CTP) and 3’-deoxyadenosine 5’-triphosphate [63] inhibit rotavirus RNA synthesis.
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Even though no treatment is approved for HAdV infections [64], different nucleos(t)ide
analogues inhibit adenovirus replication: cidofovir ((S)-HPMPC, Figure 7) [65], its lipid-ester
pro-drug brincidofovir [66], (S)-HPMPA, 2’-nor-cyclic-GMP [67], (S)-HPMPO-DAPy,
2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine (1), zalcitabine (ddC), alovudine (FddT) [68],
stampidine and compound 2 in Figure 7 [69], ganciclovir [67], and finally the ribosylated 6-azacytidine [70].
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2.2.2. Key Features of an Ideal Broad-Spectrum Nucleoside Inhibitor
An ideal broad-spectrum nucleoside inhibitor of the described viruses should target both DNA
and RNA polymerases. Structurally, the sugar moiety should be flexible enough to adapt to the
NTP pocket of both enzyme classes, limiting the choice to few options, mainly acyclic. This option
would be supported by the broad-spectrum activity against different RNA viruses found for acyclic
fleximer nucleosides [71]. Alternatively, β-D-arabinofuranose could be considered, as suggested in
Figure 8. The nucleobase should be chosen from those showing the broadest antiviral activity, such as
the fluorinated pyrazine-carboxamide of T-705 (RNA viruses), or a modified cytidine (DNA viruses).
To enhance their cell-permeability and conversion to the active tri-phosphate forms, such compounds
should be prepared in the form of pro-drugs, such as the McGuigan Pro-Tide (Figure 8) [72], present in
the blockbuster anti-HCV drug sofosbuvir [73].
The triphosphate forms of the suggested nucleoside analogues have been analyzed with docking
simulations [74] on the NTP binding pocket of the HNoV RdRp, as representative for RNA viruses,
and on the active site of our model for HAdV Pol. As exemplified for one potential structure (Figure 9),
docking results confirm the potential of these analogues to fit the active pocket of both polymerases.
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2.2.3. Non-Nucleoside Inhibitors
To date, non-nucleoside inhibitors targeting the viral polymerase have been reported only
for norovirus (Figure 10), and some have been co-crystallized with the enzyme, allowing the
identification of three allosteric sites in NoV RdRp. Suramine and NF023 bind the NTP access
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pathway between fingers and thumb sub-domains [19], naphthalene di-sulfonate NAF2 binds to
a sub-pocket of the thumb domain [24], while PPNDS binds to a second sub-region of the thumb
domain [20]. These compounds have no activity against the viral replication in cells, possibly due to
poor cell permeability [19], while the HNoV RdRp inhibitor NCI02 inhibits both HNoV and MNV
replication [75], and NIC12, a weak inhibitor of poliovirus polymerase [76], weakly inhibits MNV
replication in cells [75]. Different allosteric inhibitors of HCV polymerase were recently evaluated
as inhibitors of Caliciviridae RdRps [77]: JTK-109, TMC-647055 and Beclabuvir (Figure 10) inhibited
six Caliciviridae RdRps, spanning Norovirus, Sapovirus and Lagovirus. JTK-109 also inhibited MNV
replication in cell-based assays, providing a potential starting point to develop pan-RdRp inhibitors.
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3. Challenges and Potential Limitations to This Approach
3.1. In Vitro and In Vivo Replication Systems Available for Diarrhea-Causing Viruses
One of the main reasons for the lack of antiviral therapies against viral AGE, is the lack of suitable
cell culture systems and/or animal models for the majority of these viruses. The HNoV is not easily
cultivated in vitro or in vivo, therefore most antiviral research is being performed on the MNV or the
HNoV GI replicon. Only recently it was reported that HNoV can replicate in the human B-cell line
BJAB and in stem-cell-derived enteroids [78,79]. These models were a first breakthrough in cultivating
the HNoV but further optimization would facilitate their use in drug discovery campaigns. For HSaV
there is no in vitro or in vivo replication system available. The porcine SaV Cowden strain can infect
gnotobiotic pigs and porcine kidney cells in the presence of bile acids [80,81]. Multiple strains of
rotaviruses can be cultivated in vitro in the presence of trypsin; in vivo models to study rotavirus
infections are rather limited [82–84]. HAdVs type 40 and 41 have limited ability to replicate in cells,
when compared to other adenovirus subtypes, plus animal models are lacking [85]. Most HAstV
genotypes grow in cell culture [86] but there is no small animal model available. A murine astrovirus
model in immunodeficient mice has been reported [87], but the most widely used in vivo model are
turkey poults, which are infected with the turkey astrovirus [88].
One advantage of developing polymerase-targeting inhibitors is the availability of enzymatic
assays which allow the initial optimization of small molecule inhibitors, which can go into cellular
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assays at a later stage. These are available for multiple norovirus genotypes, for sapovirus and
adenoviruses, but not for astroviruses [19,89]. In the case of rotavirus, polymerase activity can
be assessed using purified viroplasms containing the active polymerase-capping enzyme complex
VP1-VP3 [59]. Nonetheless, the limited availability of models is a limitation for drug discovery efforts,
also because these would help to further understand the viral life cycles thus providing important
insights for the development of antiviral therapy.
3.2. Antiviral Drug Resistance
Viral replication usually has a high error rate, causing the generation of resistant mutants able to
evade a given treatment, in particular if administered long-term. This has been observed with early
anti-HIV reverse transcriptase inhibitors, but later overcome with combination therapies of drugs
belonging to different classes, with high genetic barrier to resistance, i.e., requiring multiple mutations
for the virus to become resistant [90]. Also for HCV, multi-drug treatment regimens (most of which
now include sofosbuvir) are characterized by a high barrier to resistance [91], allowing the suppression
of most HCV genotypes [92].
Although all direct-acting antiviral agents can lead to resistance, this issue would have a different
impact in the case of the acute infections, as gastroenteritis mostly is. Treatment of acute infections
aims to reduce virus replication enough to allow the immune system to clear the virus, and is therefore
of short duration [93]. The incidence and clinical impact of resistance development would therefore be
different and less likely to occur than for chronic infections.
In addition, resistant viral strains are usually less virulent than the wild type [94], and acute viral
infections still resolve in a self-limited manner. Even when treating prolonged/chronic norovirus
infections, the treatment course(s) would be expected to be short, potentially rendering the issue of
resistance less problematic in this context.
3.3. Mitochondrial Toxicity
Several drugs cause mitochondrial toxicity as a side effect, potentially leading to tissue damage
and organ failure. The main risk of mitochondrial toxicity for antivirals acting on the viral
polymerase or reverse-transcriptase is due to inhibition of the mitochondrial γDNA-polymerase [95] or
RNA-polymerase POLRMT [96]. This side-effect on the γDNA-polymerase is relevant for the anti-HIV
nucleoside reverse-transcriptase inhibitors zalzitabine (ddC), didanosine (ddI), stavudine (d4T),
zidovudine (AZT), lamivudine (3TC), abacavir (ABC) and tenofovir (TFD) [97,98]. Similarly, different
antiviral ribonucleoside analogs show toxic effects due to their affinity for POLRMT. In particular,
valopicitabine, an ester prodrug of 2CMC in phase 2 clinical trials for HCV, was not advanced
further due to gastrointestinal toxicity [99], while the triphosphate active forms of 2’-C-methyl
nucleosides 2CMC, 2CMA and 2CMG inhibit POLRMT by chain termination [100], indicating a
potential underlying issue for the development of any 2‘-C-methylated nucleoside into a drug.
However, the triphosphate form of 2CMU (uridine) does not impact POLRMT function [96], while
sofosbuvir, which combines a 2’-C-methyl feature with a 2’-fluorine substitution on the sugar,
does not cause any mitochondrial inhibition [101]. General evidence appears to indicate that
2’-monosusbtitutions, along with 4’-monosubstitutions, on the sugar of antiviral ribonucleosides
do not provide selectivity for the viral polymerase over POLRMT, with the associated mitochondrial
toxicity mainly due to the core nucleoside rather than the cleaved prodrug moieties [97].
Nonetheless, structure-activity relationships for mitochondrial toxicity remain unpredictable, and this
off-target effect can potentially be avoided with tuned modifications at both the sugar and the
nucleobase level of selected nucleoside analogues. Potential mitochondrial toxicity should thus
be carefully evaluated for each single nucleoside analogue of interest, possibly following a recently
developed screening method which combines together multiple biochemical and cellular assays to
assess this undesired effect [97].
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4. Concluding Remarks
Almost one hundred antivirals have been marketed since 1963, however mostly to treat one
specific human viral disease [4]. Given the diversity of human viral pathogens, there is the need to focus
on broad-spectrum inhibitors against viral families or even all RNA or DNA viruses. We here explored
this approach for rota-, noro-, sapo-, astro-, and adenovirus. In this review, we have emphasized
the viral polymerase by studying the functional and structural similarities between the selected
polymerases, as in our perspective this offers a starting point for broad-spectrum therapy against
diarrhea-causing viruses. The next step would be an in silico structure-based screening of nucleoside
and non-nucleoside small-molecules, using a series of molecular docking simulations on the crystal
structures or homology models of the five polymerase discussed. This strategy would allow the
identification of chemical scaffolds with good predicted affinity for all proteins at the same time, while
their subsequent assessment in enzymatic inhibition assays would provide potential broad-spectrum
hits for further optimization.
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